Antiphospholipid syndrome, thrombosis and multidisciplinary management

Kaul, Arvind; Jawad, Ali; Hughes, G. R. V.

doi:10.1002/tre.911

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This treatment can be completed by corticoids or infusion with immunoglobulin concentrates to lower the immune response, and therefore the autoantibody concentration. Other options concern anti-Plt drugs, or humanized monoclonal antibodies, like in the case of autoimmune TTP [106][107][108].…”

Section: Management Of Autoantibodiesmentioning

confidence: 99%

Generation and pathogenicity of autoantibodies associated to thrombosis and hemostasis

Amiral

2024

Explor Immunol

View full text Add to dashboard Cite

Many acquired bleeding and thrombotic complications are provoked by autoantibodies to blood coagulation factors, or to hemostasis inhibitors and regulatory proteins. If occurrence of those antibodies remains rare or ultra-rare, affected patients are not always well-identified and associated pathologies are not always understood. Today, autoantigens tend to be better characterized. New available methods allow investigating structural changes of body components, responsible for auto-immunization. This renders it possible to develop laboratory assays for detecting autoantibodies and estimating their blood concentration. This review analyzes the major autoantibodies reported to be associated with hemorrhagic or thrombotic pathologies and their possible inducing causes when known. Pathogenicity is strongly patient- and context-dependent and is related to autoantibodies’ concentration, avidity, and capacity to bind to autoantigen structures in-vivo, misdirecting the immune system to the own body’s cells or organs. Identification of autoantigens allows for developing laboratory methods for testing autoantibodies and following their evolution kinetics. In-vitro investigations concern functional assays, to evaluate autoantibody’s capacity to inhibit physiological activities, or autoantigen-capture-based assays to detect autoantibodies, like with enzyme-linked immuno-sorbent assay (ELISA) methods. Exploring patients with autoimmune complications remains difficult as few specific assays are available. They mainly concern diseases with the highest incidence, like anti-phospholipid antibodies, lupus anticoagulants, or heparin-dependent antibodies. The present understanding suggests that antibodies to ubiquitous components, like phospholipids or polysaccharides, are actually targeted to proteins with a strong affinity binding to those components: Autoantibodies are not directed to phospholipids, but to phospholipid-binding proteins, and heparin-dependent antibodies are not directed to anticoagulant polysaccharides, but to platelet factor 4. Most pathogenic autoantibodies are of immunoglobulin G (IgG) isotype, but in some cases, IgM or IgA isotypes can be involved. Identification and characterization of autoantibodies associated to hemorrhagic or thrombotic pathologies remains complex at the laboratory level, although they are of high relevance for the right management of concerned patients.

show abstract

Section: Management Of Autoantibodiesmentioning

confidence: 99%

Generation and pathogenicity of autoantibodies associated to thrombosis and hemostasis

Amiral

2024

Explor Immunol

View full text Add to dashboard Cite

show abstract

Antiphospholipid syndrome, thrombosis and multidisciplinary management

Cited by 1 publication

References 26 publications

Generation and pathogenicity of autoantibodies associated to thrombosis and hemostasis

Generation and pathogenicity of autoantibodies associated to thrombosis and hemostasis

Contact Info

Product

Resources

About